Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis

Peng, Peijian; Cheng, Hua; Ou, Xue‐Qing; Zeng, Linjuan; Wu, Xuan; Liu, Yumeng; Tang, Yanna; Wang, Siyang; Zhang, Hongyu; Chen, Zhibin

doi:10.2147/dddt.s67592

Cited by 12 publications

(13 citation statements)

References 25 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S-1 and capecitabine are two oral anticancer agents that may act as substitutes for 5-FU, with sufficient efficacy and relatively low toxicity profiles, offering an attractive choice for patients who have been significantly jeopardized by the complications caused by prior courses of palliative chemoradiotherapy. 25,26 Published data have proved their efficacy in various solid tumors, including NPC; [27][28][29][30][31][32][33][34][35][36][37][38] however, their utilization as maintenance therapy for mNPC has not been reported. Whether the use of these two oral agents in the maintenance phase could benefit mNPC patients who responded to previous systemic chemotherapy and radiotherapy remains unknown.…”

Section: Introductionmentioning

confidence: 99%

<p>Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience</p>

Guo

Chen

Han

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: In this study, we retrospectively evaluated a series of metastatic nasopharyngeal carcinoma (mNPC) patients who received oral maintenance chemotherapy using S-1/capecitabine after systemic chemotherapy and local radiation therapy, and aimed to explore potential efficient treatment strategies for this subset of patients. Patients and Methods: Thirty-seven patients with mNPC (19 newly diagnosed metastatic patients and 18 metastatic cases after definitive chemoradiotherapy) who received the treatment strategies mentioned above were analyzed. Results: After a median follow-up time of 37 months, the 3-year progression-free survival and overall survival (OS) rates were 47.6% and 87.7%, respectively. The median time to progression was 27.6 months, while the median OS was not reached at time of last follow-up. The most common acute adverse events were hematological and gastrointestinal toxicity, and all were tolerable and curable. Conclusion: Oral maintenance chemotherapy using S-1/capecitabine in mNPC patients after systemic chemotherapy could yield a superb outcome. Further multicenter prospective clinical trials are warranted.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience</p>

Guo

Chen

Han

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…CDHP can enhance the efficacy and OXO can reduce the toxicity of tegafur, respectively. 13 , 14 Since inception, S-1 has been frequently used in gastrointestinal tumors. But more and more research has demonstrated that S-1 can provide significant effects on the survival rates in head and neck cancer.…”

Section: Discussionmentioning

confidence: 99%

A retrospective study of concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy on curative effect for treatment of patients with N3 stage nasopharyngeal carcinoma

Zhang¹,

Zhou²,

Huang³

et al. 2018

CMAR

View full text Add to dashboard Cite

IntroductionThe purpose of this study was to analyze the efficacy and safety of concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy for N3 stage nasopharyngeal carcinoma (NPC).MethodsThis study included 44 N3 stage NPC patients treated with concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy. The intensity-modulated radiation therapy doses were planning target volume (PTV) 70–72 Gy for gross disease in the nasopharynx and 66–70 Gy for positive lymph nodes. The doses for high-risk- and low-risk region PTV were 60–62 and 54–56 Gy in 31–33 fractions. All patients received a concurrent chemotherapy program consisting of cisplatin 100 mg/m2, day 1, and the cycle repetition was every 21 days. The adjuvant chemotherapy program consisted of 4 cycles of S-1. The dose of S-1 was determined according to the body surface area (BSA): 40 mg twice a day for BSA <1.25 m2; 50 mg twice a day for 1.25 m2≤BSA<1.5 m2; and 60 mg twice a day for BSA ≥1.5 m2. S-1 was given on days 1–28, given 6 weeks apart.ResultsAll 44 patients completed at least 2 cycles of concurrent chemotherapy and 4 cycles of adjuvant chemotherapy. The total efficiency of therapy was 100.0%. The 3-year overall survival (OS), distant metastasis-free survival (DMFS), local-regional control, and progression-free survival rates were 86.4%, 84.1%, 97.7%, and 81.8%, respectively. There were no differences in the OS, DMFS, and efficiency between fast-fading group (reaching partial response before the second cycle of concurrent chemotherapy) and general-fading group (the rest of the group). The incidence of rash in the entire group was low, and there was also no association with prognosis.ConclusionIn patients with N3 stage NPC, concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy yielded an excellent survival benefit, and the toxicities were mild and tolerable. Distant metastasis was the main cause of treatment failure.

show abstract

“…Platinum drugs have been the most widely used chemotherapeutic drugs since they were put into clinical application in the 1970s [ 8 , 9 ]. Clinically, platinum drugs have been extensively used in the treatment of malignant tumors such as nasopharyngeal carcinoma [ 10 ], esophageal cancer [ 11 ], breast cancer [ 12 ], etc. Therefore, platinum drugs have become a symbol of an era among anticancer drugs [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Objective To explore the relationship between ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in ovarian cancer by the method of meta-analysis. Methods Pubmed, Web of Science, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), and China Wanfang databases were comprehensively searched up to September 2020, to identify the relationship between ERCC1 rs11615 polymorphism and chemosensitivity of ovarian cancer. The data was analyzed by Stata 15.0 statistic software. Results A total of 10 published papers were included, including 1866 patients with ovarian cancer. The results showed that compared allele C at ERCC1 rs11615 locus with allele T, the pooled OR was 0.92 (95%CI:0.68 ~ 1.24, P > 0.05). There were no significant differences in recessive, dominant, homozygous, and heterozygous models. In accordance with a subgroup analysis of Ethnicity, all genotypes were statistically significant in the Asian population. In the allelic, dominant, recessive, homozygous and heterozygous models, the OR was 0.70 (95%CI:0.51 ~ 0.95), 0.20 (95%CI:0.07 ~ 0.56), 0.79 (95%CI:0.63 ~ 1.00), 0.21 (95%CI:0.07 ~ 0.59), 0.19 (95%CI:0.07 ~ 0.54), respectively, while in the Caucasian population, no statistically significant genotype was found. Conclusion The ERCC1 rs11615 polymorphism is associated with chemosensitivity in patients with ovarian cancer, especially in the Asian population, but not in the Caucasian population.

show abstract

Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis

Cited by 12 publications

References 25 publications

<p>Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience</p>

<p>Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience</p>

A retrospective study of concurrent chemoradiotherapy plus S-1 adjuvant chemotherapy on curative effect for treatment of patients with N3 stage nasopharyngeal carcinoma

ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About